Wall Street analysts predict that Microbot Medical Inc (NASDAQ:MBOT) will report ($0.27) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Microbot Medical’s earnings. Microbot Medical reported earnings per share of ($0.36) in the same quarter last year, which would suggest a positive year over year growth rate of 25%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, August 12th.
On average, analysts expect that Microbot Medical will report full year earnings of ($1.15) per share for the current year. For the next financial year, analysts forecast that the business will report earnings of ($1.30) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Microbot Medical.
Microbot Medical (NASDAQ:MBOT) last released its earnings results on Friday, May 15th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03).
MBOT stock traded down $0.16 on Thursday, reaching $6.13. 1,343 shares of the company’s stock were exchanged, compared to its average volume of 116,064. The company has a current ratio of 32.47, a quick ratio of 32.47 and a debt-to-equity ratio of 0.02. Microbot Medical has a twelve month low of $4.30 and a twelve month high of $20.15. The stock has a fifty day moving average of $7.03 and a 200-day moving average of $8.01.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sunbelt Securities Inc. bought a new stake in shares of Microbot Medical during the fourth quarter worth about $4,073,000. Steward Partners Investment Advisory LLC lifted its stake in Microbot Medical by 420.0% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 15,600 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 12,600 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Microbot Medical by 16.1% in the 1st quarter. BlackRock Inc. now owns 212,332 shares of the biotechnology company’s stock worth $1,179,000 after buying an additional 29,436 shares during the last quarter. Finally, Morgan Stanley increased its holdings in shares of Microbot Medical by 353.2% in the 1st quarter. Morgan Stanley now owns 18,521 shares of the biotechnology company’s stock worth $103,000 after buying an additional 14,434 shares during the last quarter. 9.88% of the stock is currently owned by hedge funds and other institutional investors.
Microbot Medical Company Profile
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.